Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BGR-34,Glibenclamide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
AIIMS Researchers Find Ayurvedic-Allopathic Combo BGR-34 & Glibenclamide in Controlling Diabetes
Details : In the Animal experimental study, doctors have found that the pace of diabetes growth can be halted if allopathic drug is integrated with BGR-34, a herbal formulation enriched with antioxidant properties which stops bad cholesterol from accumulating in t...
Product Name : BGR-34
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
March 02, 2021
Lead Product(s) : BGR-34,Glibenclamide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : CSIR-Indian Institute of Chemical Technology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AIIMS Find Ivermectin Prophylaxis Reduces Infection in Covid-19 Patients
Details : A study by All India Institutes of Medical Sciences (AIIMS)-Bhubaneswar in the Indian state of Odisha found that two doses of potential drug ivermectin prophylaxis resulted in a 73% reduction in Covid-19 infection.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
